TriangleNCT00354835 · OUTCOME
Incidence of Bladder Dysfunction
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Participant
- Interval / dispersion
- Not reported
- Time frame
- 3-6 years after enrollment
What was measured
Number of patients with a summary score greater than 8.5
Analysis population: 470 participants were excluded due to ineligibility or absence of the dysfunctional voiding and incontinence symptoms questionnaire.
Groups in this outcome
Vincristine, Dactinomycin, Cyclophosphamide (VAC)
Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
VAC Alternating With Vincristine, Irinotecan (VI)
Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
| Group | Source count |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 7 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 2 | Not reported | Not reported | Not reported | Not reported |
| VAC Alternating With Vincristine, Irinotecan (VI) | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 4
- units
- Participants
- description
- Number of patients with a summary score greater than 8.5
- groups
- description
- Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
- id
- OG000
- title
- Vincristine, Dactinomycin, Cyclophosphamide (VAC)
- description
- Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
- id
- OG001
- title
- VAC Alternating With Vincristine, Irinotecan (VI)
- param Type
- NUMBER
- population Description
- 470 participants were excluded due to ineligibility or absence of the dysfunctional voiding and incontinence symptoms questionnaire.
- reporting Status
- POSTED
- time Frame
- 3-6 years after enrollment
- title
- Incidence of Bladder Dysfunction
- type
- SECONDARY
- unit Of Measure
- Participant
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice